This database contains 429 studies, archived under the term: "USA"
Click here to filter this large number of results.
Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression
Wang, Lucy Y.,
Shofer, Jane B.,
Rohde, Kirsten,
Hart, Kim L.,
Hoff, David J.,
McFall, Yun H.,
Raskind, Murray A.,
Peskind, Elaine R.
Objectives: Agitation/aggression in Alzheimer disease (AD) is a major cause of patient distress, caregiver burden, and institutionalization. Enhanced behavioral responsiveness to central nervous system norepinephrine (NE) release may contribute to the pathophysiology of agitation/aggression in AD. Prazosin, a nonsedating generic medication used for hypertension and benign prostatic hypertrophy, antagonizes NE effects at brain postsynaptic alpha-1 […]
Video decision support tool for advance care planning in dementia: randomised controlled trial
Volandes, Angelo E.,
Paasche-Orlow, Michael K.,
Barry, Michael J.,
Gillick, Muriel R.,
Minaker, Kenneth L.,
Chang, Yuchiao,
Cook, E. Francis,
Abbo, Elmer D.,
El-Jawahri, Areej,
Mitchell, Susan L.
Objective: To evaluate the effect of a video decision support tool on the preferences for future medical care in older people if they develop advanced dementia, and the stability of those preferences after six weeks.; Design: Randomised controlled trial conducted between 1 September 2007 and 30 May 2008. Setting Four primary care clinics (two geriatric […]
Using video images to improve the accuracy of surrogate decision-making: a randomized controlled trial
Introduction: When patients are unable to make important end-of-life decisions, doctors ask surrogate decision makers to provide insight into patients’ preferences. Unfortunately, multiple studies have shown that surrogates’ knowledge of patient preferences is poor. We hypothesized that a video decision tool would improve concordance between patients and their surrogates for end-of-life preferences.; Objective: To compare […]
Therapeutic conversation to improve mood in nursing home residents with Alzheimer’s disease
Few studies have tested strategies to address the mental health needs of individuals with Alzheimer’s disease (AD). To test a newly developed, empirically based modified counseling approach, 30 nursing home residents with AD were randomly assigned to a modified counseling (Therapeutic Conversation) treatment group or usual care control group. Mini-Mental State Examination mean scores were […]
New insights into clinical trial for Colostrinin in Alzheimer’s disease
Szaniszlo, P.,
German, P.,
Hajas, G.,
Saenz, D. N.,
Kruzel, M.,
Boldogh, I.
Background: The pathomechanism of Alzheimer’s disease (AD) is multifactorial although the most popular hypotheses are centered on the effects of the misfolded, aggregated protein, amyloid beta (Abeta) and on Tau hyperphosphorylation.; Objectives: Double blinded clinical trials were planned to demonstrate the effect of Colostrinin (CLN) on instrumental daily activities of AD patients. The potential molecular […]
Engaging communities in evidence-based interventions for dementia caregivers
Caring for a family member with dementia is associated with unique stressors and burdens related to caregiving. Delivering interventions with proven efficacy to dementia caregivers remains a challenge because of the complexity of providing psychosocial support and skills training for caregivers within current models of formal healthcare services. This article focuses on implementation research and […]
Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial
Snitz, Beth E.,
O'Meara, Ellen S.,
Carlson, Michelle C.,
Arnold, Alice M.,
Ives, Diane G.,
Rapp, Stephen R.,
Saxton, Judith,
Lopez, Oscar L.,
Dunn, Leslie O.,
Sink, Kaycee M.,
DeKosky, Steven T.
Context: The herbal product Ginkgo biloba is taken frequently with the intention of improving cognitive health in aging. However, evidence from adequately powered clinical trials is lacking regarding its effect on long-term cognitive functioning.; Objective: To determine whether G. biloba slows the rates of global or domain-specific cognitive decline in older adults.; Design, Setting, and […]
Long-term effects of rivastigmine capsules in patients with traumatic brain injury
Silver, Jonathan M.,
Koumaras, Barbara,
Meng, Xiangyi,
Potkin, Steven G.,
Reyes, Patricio F.,
Harvey, Philip D.,
Katz, Douglas I.,
Gunay, Ibrahim,
Arciniegas, David B.
Objective: To investigate the safety, tolerability and efficacy of rivastigmine capsules (3-12 mg/day) in a 26-week, multi-centre, open-label extension of a double-blind study.; Methods: Patients with traumatic brain injury (TBI) and persistent cognitive impairment who had received rivastigmine (3-6 mg/day) or placebo for 12 weeks could enter the extension study and receive rivastigmine (< or […]
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S.,
Sperling, R.,
Gilman, S.,
Fox, N. C.,
Blennow, K.,
Raskind, M.,
Sabbagh, M.,
Honig, L. S.,
Doody, R.,
van Dyck, C. H.,
Mulnard, R.,
Barakos, J.,
Gregg, K. M.,
Liu, E.,
Lieberburg, I.,
Schenk, D.,
Black, R.,
Grundman, M.
Background: Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD.; Methods: The study enrolled 234 patients, randomly assigned to IV bapineuzumab or placebo in 4 dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg). […]